News
-
Aclarion Announces Reverse Stock Split
January 2, 2024 -
Aclarion Announces Key Commercial Milestone With Completion of 1,000 Nociscan Exams
November 27, 2023 -
Aclarion Announces Achievement of Goal to Enroll 10 Leading Spine Surgery Key Opinion Leaders (KOLs) to Support Nociscan Adoption
November 8, 2023 -
Aclarion Expands Immediate Nociscan Access Into New York City With Tenth Key Opinion Leader Surgeon Advisor Addition Roger Hartl, MD
November 6, 2023 -
Aclarion Presents at the NIH HEAL Initiative Fall Meeting
November 1, 2023 -
Aclarion Announces Signing of Commercial Agreement With Porter Hospital, an AdventHealth facility, to Bring Nociscan Technology to Denver
October 25, 2023 -
Aclarion Announces Nociscan® Cost-Effectiveness Poster Presented at 45th Annual SMDM Meeting
October 24, 2023 -
Aclarion Announces Signing Strategic Partnership Letter of Intent With ATEC to Advance Commercialization of Nociscan
October 23, 2023 -
Aclarion Provides Updated Investor Presentation and Corporate Update
October 2, 2023 -
Aclarion, Inc. Announces Filing of Delayed 10-Q Quarterly Report
August 25, 2023